- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01844297
Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy
Efficacy and Safety of Tenofovir Disoproxil Fumarate Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy for ART-naive Chinese Patients With HIV-1 Infection
Studieoversigt
Detaljeret beskrivelse
This study is a prospective, open-label, multi-centered clinical trial to assess the virologic suppression and immune recovery rates as well as tolerability of the regimen 3TC+TDF+EFV in ARV-naive Chinese population.
500 eligible participants will be recruited to take the regimen If the patient fails to tolerate EFV, it can be substituted by NVP when CD4 < 250/μL, and by LPV/r when CD4 > 250/uL. If the patient fails to tolerate TDF, AZT will be an alternative, except when Hb < 90/L or neutrophil count < 0.75×109/L. The participants will be followed up by months 0.5, 1, 2 ,3 and every 3 months subsequently for 2 years.
The efficacy of the regimen will be evaluated by comparison between different points along the time line and previous regimens. The safety of the regimen will be assessed by monitoring kidney function, bone density, cardiovascular profile, lipid profile, liver function etc as well as other adverse events.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Beijing
-
Beijing, Beijing, Kina, 100730
- Peking Union Medical College Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- age between 18-65 years of either gender
- HIV-1 antibody seropositive detected by ELISA and confirmed by western blot
- CD4 cell count < 500/ul
- Signed informed consent, with no condition that precludes follow-up for 2 years
- No plan to move out of the area during the trial
- antiretroviral therapy naive
Exclusion Criteria:
- patients in acute phase of HIV infection
- patients with ongoing opportunistic infection or AIDS-related malignancies; or with opportunistic infection within previous 3 months and still unstable within 14 days before inclusion
patients with the any of the following test results during screening for inclusion:
- WBC count < 2000/ul,
- neutrophil count < 1000/ul,
- Hb < 9g/dl,
- platelet count < 75000/ul,
- serum creatinine > 1.5 ULN,
- transaminases or alkaline phosphatase > 3 ULN,
- total bilirubin > 2 ULN,
- serum creatinine kinase > 2 ULN
- CCr < 60ml/min
- Pregnancy and breastfeeding
- Intravenous drug user
- Severe neuropathy or mental disorder
- history of alcohol abuse and unable to withdrawal
- Severe peptic ulcer disease
- Non-Chinese nationality
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Andet: TDF+3TC+EFV
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48
Tidsramme: 48 weeks
|
48 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96
Tidsramme: 96 weeks
|
96 weeks
|
Percentage of Participants With HIV-1 RNA < 40 Copies/mL at Week 96
Tidsramme: 96 weeks
|
96 weeks
|
Change From Baseline in CD4 count at Week 48
Tidsramme: Baseline and 48 weeks
|
Baseline and 48 weeks
|
Change From Baseline in CD4 count at Week 96
Tidsramme: Baseline and 96 weeks
|
Baseline and 96 weeks
|
Incidence of adverse events and laboratory abnormalities from baseline to week 48
Tidsramme: 48 weeks
|
48 weeks
|
Incidence of adverse events and laboratory abnormalities from baseline to week 96
Tidsramme: 96 weeks
|
96 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Fan H, Guo F, Hsieh E, Chen WT, Lv W, Han Y, Xie J, Li Y, Song X, Li T. Incidence of hypertension among persons living with HIV in China: a multicenter cohort study. BMC Public Health. 2020 Jun 1;20(1):834. doi: 10.1186/s12889-020-08586-9.
- Luo L, Wang N, Yue Y, Han Y, Lv W, Liu Z, Qiu Z, Lu H, Tang X, Zhang T, Zhao M, He Y, Shenghua H, Wang M, Li Y, Huang S, Li Y, Liu J, Tuofu Z, Routy JP, Li T. The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study. BMC Infect Dis. 2019 Mar 14;19(1):257. doi: 10.1186/s12879-019-3847-0.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- CACT1215
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med AIDS/HIV PROBLEM
-
Peking Union Medical CollegeUkendt
-
University of MinnesotaTrukket tilbageHIV-infektioner | HIV/AIDS | Hiv | AIDS | Aids/Hiv problem | AIDS og infektionerForenede Stater
-
Peking Union Medical CollegeMinistry of Science and Technology of the People´s Republic of ChinaUkendt
-
University Hospital, GrenobleSociété Française d'Anesthésie et de RéanimationAfslutteteFast Diagnosis Performance in Guiding First Aid Resuscitation and HemostasisFrankrig
-
Pennington Biomedical Research CenterAfsluttetKvindelige reproduktive problem | Mandligt reproduktivt problemForenede Stater
-
Babes-Bolyai UniversityThe Executive Agency for Higher Education, Research, Development and...AfsluttetFølelsesmæssigt problemRumænien
-
University of AarhusAfsluttetStressrelateret problemDanmark
-
Anne Dahl RefshaugeUniversity of AarhusAfsluttet
-
Universidad Miguel Hernandez de ElcheRekrutteringFølelsesmæssigt problemSpanien
-
University of FloridaNational Institute on Drug Abuse (NIDA)Ikke rekrutterer endnu
Kliniske forsøg med TDF+3TC+EFV
-
Gilead SciencesAfsluttet
-
National Center for AIDS/STD Control and Prevention...Gilead SciencesAfsluttet
-
The HIV Netherlands Australia Thailand Research...Mylan LaboratoriesAfsluttet
-
Juan A. ArnaizUkendt
-
Yu-Jay Corp.Afsluttet
-
HeNan Sincere Biotech Co., LtdBeijing YouAn Hospital; Beijing Ditan Hospital; Peking Union Medical College... og andre samarbejdspartnereAfsluttet
-
French National Agency for Research on AIDS and...Merck Sharp & Dohme LLCAfsluttet
-
ANRS, Emerging Infectious DiseasesUniversity of KwaZulu; Africa Centre For Health and Population StudiesAfsluttet
-
Peking Union Medical CollegeUkendt
-
Mahidol UniversityUkendt